COMPASS Pathways Plc CMPS

Healthcare Biotechnology

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

NDAQ:CMPS - Post by User

COMPASS Pathways Plc

<< Previous

Bullboard Posts

Next >>

Post by Streetbrainon Nov 28, 2020 10:58pm

775 Views

Post# 31995986

Next Unicorns In Psychedelics Motely Fool Picks

Motely Fool seems to pick some interesting leaders here with tremedous growth for mindmed $MMED and cybin $CYBN to catch up to Compass Pathways $CMPS. Both Mindmed and Cybin have very similar cash positions and listed on Neo both seem to be planning on heading to Nasdaq.

Compass is chasing GW pharma its excited very bullish on Compass. But looking out for these two next

https://www.fool.com/investing/2020/11/25/missed-out-on-marijuana-stocks-psychedelic-stocks/

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 8, 2024)